Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H9N3.2ClH |
Molecular Weight | 184.067 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.NCCC1=CNC=N1
InChI
InChIKey=PPZMYIBUHIPZOS-UHFFFAOYSA-N
InChI=1S/C5H9N3.2ClH/c6-2-1-5-3-7-4-8-5;;/h3-4H,1-2,6H2,(H,7,8);2*1H
Molecular Formula | C5H9N3 |
Molecular Weight | 111.1451 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Histamine is a depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and a centrally acting neurotransmitter. Phosphate salt of jistamine was used as a diagnostic aid for evaluation of gastric acid secretory function. In addition, this compound is used as a positive control in evaluation of allergenic (immediate hypersensitivity or "Type I") skin testing. In addition, histamine is being studied for treatment of multiple sclerosis. It was approved, that histamine physiological functions are mediated by four 7-transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacological intervention. The receptors display molecular heterogeneity and constitutive activity. H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R led to the development of H2R-antagonists that revolutionized stomach ulcer treatment. The H3R is an auto receptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons. The H4R occurs on immuncompetent cells and the development of anti-inflammatory drugs is anticipated.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16648669 |
|||
Target ID: CHEMBL1941 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26084539 |
|||
Target ID: CHEMBL264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17652997 |
|||
Target ID: CHEMBL3759 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26084539 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | HISTAMINE PHOSPHATE Approved UseIndications and Usage Uses temporarily relieves symptoms due to sinus discomforts associated with inflamed sinuses, hay fever or upper respiratory allergies: sinus pain and pressure runny nose sinus headaches sore throat nasal congestion dry mucus membranes sneezing itchy, burning eyes Reference image sinus.jpg Launch Date1939 |
|||
Primary | Unknown Approved UseUnknown |
|||
Diagnostic | HISTAMINE PHOSPHATE Approved UseHistamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function. Anacidity (achlorhydria) in response to histamine may indicate pernicious anemia, atrophic gastritis, adenomatous polyps of stomach, or gastric carcinoma. Gastric hypersecretion in response to histamine may indicate duodenal ulcer or the Zollinger-Ellison syndrome. Launch Date1939 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
39 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12092744 |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
HISTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1877 nM × min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12092744 |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
HISTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 min EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12092744 |
1 mg single, subcutaneous dose: 1 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
HISTAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
0.03 mg single, intravenous Highest studied dose Dose: 0.03 mg Route: intravenous Route: single Dose: 0.03 mg Sources: |
unhealthy n = 4 Health Status: unhealthy Condition: asthma Sex: M Population Size: 4 Sources: |
|
0.2 mg single, intramuscular Highest studied dose Dose: 0.2 mg Route: intramuscular Route: single Dose: 0.2 mg Sources: |
unhealthy n = 1 Health Status: unhealthy Condition: asthma Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Diesel exhaust particulates upregulate histamine receptor mRNA and increase histamine-induced IL-8 and GM-CSF production in nasal epithelial cells and endothelial cells. | 1999 Jan |
|
Involvement of glutamate in transmission of afferent constrictive inputs from the airways to the nucleus tractus solitarius in ferrets. | 2000 Apr 12 |
|
Identification of a histamine H(3)-like receptor in the zebrafish (Danio rerio) brain. | 2000 Aug |
|
Possible contribution of stem cell factor in psoriasis vulgaris. | 2000 Dec |
|
Histamine H(3) receptors depress synaptic transmission in the corticostriatal pathway. | 2001 |
|
Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. | 2001 Feb |
|
Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. | 2001 Feb |
|
No correlation between wine intolerance and histamine content of wine. | 2001 Feb |
|
Acquisition and alteration of adhesion molecules during cultured human mast cell differentiation. | 2001 Feb |
|
Inhibitory action of water soluble fraction of Terminalia chebula on systemic and local anaphylaxis. | 2001 Feb |
|
Chronic tobacco smoke exposure increases airway sensitivity to capsaicin in awake guinea pigs. | 2001 Feb |
|
A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses. | 2001 Feb |
|
Ontogeny of modulatory inputs to motor networks: early established projection and progressive neurotransmitter acquisition. | 2001 Feb 15 |
|
The activation of synovial mast cells: modulation of histamine release by tryptase and chymase and their inhibitors. | 2001 Feb 2 |
|
Food-deprived activity stress decreased the activity of the histaminergic neuron system in rats. | 2001 Feb 9 |
|
Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. | 2001 Jan |
|
Preclinical profile of the monodisperse iodinated macromolecular blood pool agent P743. | 2001 Jan |
|
Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. | 2001 Jan |
|
The treatment of rhinovirus infections: progress and potential. | 2001 Jan |
|
Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo. | 2001 Jan |
|
Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. | 2001 Jan |
|
Effects of cetirizine and epinastine on the skin response to histamine iontophoresis. | 2001 Jan |
|
Acidification of formula reduces bacterial translocation and gut colonization in a neonatal rabbit model. | 2001 Jan |
|
Regulatory effect of histamine H1 receptor antagonist on the expression of messenger RNA encoding CC chemokines in the human nasal mucosa. | 2001 Jan |
|
Role of kinins in seasonal allergic rhinitis: icatibant, a bradykinin B2 receptor antagonist, abolishes the hyperresponsiveness and nasal eosinophilia induced by antigen. | 2001 Jan |
|
Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. | 2001 Jan |
|
Expression and biological significance of Ca2+-activated ion channels in human keratinocytes. | 2001 Jan |
|
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). | 2001 Jan |
|
Neurotransmitter release from bovine adrenal chromaffin cells is modulated by capacitative Ca(2+)entry driven by depleted internal Ca(2+)stores. | 2001 Jan |
|
Identification of rat H3 receptor isoforms with different brain expression and signaling properties. | 2001 Jan |
|
delta-opioid receptors inhibit neurogenic intestinal secretion evoked by mast cell degranulation and type I hypersensitivity. | 2001 Jan 1 |
|
Luminal Nalpha-methyl histamine stimulates gastric acid secretion in duodenal ulcer patients via releasing gastrin. | 2001 Jan 26 |
|
Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. | 2001 Jan 8 |
|
Approaches to healing and prophylaxis of nonsteroidal anti-inflammatory drug-associated ulcers. | 2001 Jan 8 |
|
Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity. | 2001 Mar |
|
Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. | 2001 Mar 2 |
|
Glycine receptor mediated responses in rat histaminergic neurons. | 2001 Mar 2 |
|
Correlation between neutral endopetidase (NEP) 3.4.24.11 in serum and the degree of the bronchial hyperreactivity. | 2001 Mar 2 |
|
Regulation of tight junction permeability and occludin phosphorylation by Rhoa-p160ROCK-dependent and -independent mechanisms. | 2001 Mar 30 |
|
Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: regulation by gastrin. | 2001 Mar 9 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/histamine-phosphate.html
The skin in the test area should be cleansed with alcohol and air dried.
The histamine control skin test solution should be placed at the same site with the other skin test antigens, either on the patient's back or on the volar surface of the forearm. The patient should be placed in a comfortable position before the testing is begun.
For the prick test, a sharp needle is used to puncture the skin, but not to draw blood. If the scratch test is used, carefully break or scratch the skin with a sterile scarifier. Do not draw blood. Each scratch should be about 2 mm - 4 mm in length.
A small drop of the histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) is placed on the abraded skin site no closer than 4 or 5 cm from an adjacent test site. Some physicians prefer to place the solution on the test area and then prick through the drop with a sharp needle.
Route of Administration:
Parenteral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17359382
Histamine prevented monocytic apoptosis induced by serum deprivation, CD95/Fas ligation, or dexamethasone in a dose- and time-dependent fashion. The inhibitory effects of histamine on monocytic apoptosis were blocked by an H2R antagonist, and mimicked by an H2R agonist. Histamine also up-regulated the expression of Bcl-2 and Mcl-1, and inhibited the activation of caspase-3. The culture supernatants from histamine-treated monocytes inhibited monocytic apoptosis, which was partly reversed by the removal of IL-10. Monocytes cultured with anti-IL-10 mAb and histamine did not exhibit an inhibitory effect on apoptosis. The histamine-induced anti-apoptotic effect was attenuated when monocytes were cultured in the presence of a cAMP inhibitor.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:17:19 GMT 2023
by
admin
on
Fri Dec 15 17:17:19 GMT 2023
|
Record UNII |
3POA0Q644U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
CEPLENE (AUTHORIZED: LEUKEMIA, MYELOID, ACUTE)
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/05/272
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
||
|
NCI_THESAURUS |
C2139
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
||
|
WHO-ATC |
L03AX14
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
||
|
WHO-VATC |
QL03AX14
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ALLERGEN SCRATCH EXTRACT POSITIVE CONTROL "TORII" HISTAMINE DIHYDROCHLORIDE
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | APPROVED SEPTEMBER 2015 | ||
|
1309009
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
100000089203
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
3POA0Q644U
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
Histamine dihydrochloride
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
SUB12022MIG
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
m6026
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL90
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
5818
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
257873
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
C1734
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
SUB14108MIG
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
DBSALT002193
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
56-92-8
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
DTXSID1058767
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
142136
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
200-298-4
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
3POA0Q644U
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
PRIMARY | |||
|
350466
Created by
admin on Fri Dec 15 17:17:20 GMT 2023 , Edited by admin on Fri Dec 15 17:17:20 GMT 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |